Lab-Grown Immune Commanders Could Democratise Cancer Therapy
UBC scientists have grown helper T cells from stem cells for the first time, potentially unlocking affordable, off-the-shelf cancer immunotherapy.
For the first time, researchers at the University of British Columbia have reliably grown helper T cells from stem cells in a controlled laboratory setting.
Helper T cells are the immune system's coordinators — they don't fight cancer directly but tell other immune cells to fight harder and longer. This has been a fundamental missing piece in cancer immunotherapy.
Current CAR-T treatments, which reprogram a patient's own T cells to attack tumours, cost $400,000+ per treatment and must be custom-made for each patient. If helper T cells can be mass-produced from stem cells, off-the-shelf immune treatments could become both more effective and dramatically cheaper.
Key Facts
- First reliable method for growing helper T cells from stem cells (ScienceDaily)
- Current CAR-T therapy costs: $400,000+ per patient, custom-made
- Helper T cells coordinate the entire immune response against cancer
- Confirmed by World Stem Cell Summit
Why This Matters
Immunotherapy has revolutionised cancer treatment but remains limited by cost and complexity. Each CAR-T treatment takes weeks to manufacture from the patient's own cells. Growing universal helper T cells from stem cells could transform immunotherapy from boutique medicine to broadly accessible treatment — the difference between a $400,000 custom therapy and something available at your local hospital.
What We Don't Know Yet
Lab-grown cells don't equal clinical therapy — years of trials lie ahead. Helper T cells alone don't kill cancer; they enhance other immune responses. Immune rejection of "off-the-shelf" cells remains a significant challenge. And the regulatory pathway for stem-cell-derived immune products is complex and slow.
Sources: ScienceDaily · World Stem Cell Summit
Published 17 February 2026 · Category: Health & Medicine